Year: 2026
Type: article
Abstract: For over 40 years, percentage blood basophils has been used to estimate survival and to define the accelerated phase [ 1 , 2 , 3 , 4 , 5 , 6 ]. Recently, this use has declined or disappeared, especially since the introduction of tyrosine kinase inhibitor (TKI) therapy. No widely used CML survival prediction model includes percentage blood basophils [ 7 ]. Putting a nail in the coffin, the 2022 WHO classification of myeloid neoplasms, for good reason, eliminated accelerated phase CML making percentage blood basophils irrelevant [ 8 ]. In contrast, the 2022 International Consensus Classification (ICC) retained accelerated phase CML. The 2025 European LeukemiaNet classification seems undecided [ 9 , 10 ] (reviewed in refs. [ 11 , 12 ]).
Source: Leukemia
Institutions: University Hospital Olomouc, Palacký University Olomouc, Peking University People's Hospital, VSB - Technical University of Ostrava, Masaryk University, University Hospital Brno, Institute of Haematology and Blood Transfusion, Charles University, University Hospital Hradec Králové, University Hospital Ostrava, General University Hospital in Prague, Fred Hutch Cancer Center, Imperial College London
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,190
OpenAlex ID: W7137276884